PubMed

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

Ann Intern Med. 2003 Nov 18;139(10):810-6.PMID: 14623618 [PubMed - indexed for MEDLINE]Related articlesFree article

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

AIDS. 2003 Mar 28;17(5):711-20.PMID: 12646794 [PubMed - indexed for MEDLINE]Related articles

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.PMID: 12693883 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of adherence on CD4 cell count responses among HIV-infected patients.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):261-8.PMID: 15076240 [PubMed - indexed for MEDLINE]Related articles

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

AIDS. 2006 May 12;20(8):1117-23.PMID: 16691062 [PubMed - indexed for MEDLINE]Related articles

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.PMID: 14517122 [PubMed - indexed for MEDLINE]Related articlesFree article

Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA.

BMC Health Serv Res. 2008 Nov 20;8:241.PMID: 19021908 [PubMed - indexed for MEDLINE]Related articlesFree article

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.

Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group.

AIDS. 2001 May 25;15(8):983-90.PMID: 11399980 [PubMed - indexed for MEDLINE]Related articles

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.PMID: 14970148 [PubMed - indexed for MEDLINE]Related articlesFree article

CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.

Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS.

HIV Med. 2006 Sep;7(6):383-8.PMID: 16903983 [PubMed - indexed for MEDLINE]Related articles

Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

Antivir Ther. 2004 Apr;9(2):229-35.PMID: 15134185 [PubMed - indexed for MEDLINE]Related articles

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.PMID: 15319852 [PubMed - indexed for MEDLINE]Related articles

Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.

Antivir Ther. 2004 Oct;9(5):713-9.PMID: 15535408 [PubMed - indexed for MEDLINE]Related articles

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.PMID: 16323104 [PubMed - indexed for MEDLINE]Related articles

Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.PMID: 14523280 [PubMed - indexed for MEDLINE]Related articles

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.PMID: 11434728 [PubMed - indexed for MEDLINE]Related articlesFree article

Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):289-95.PMID: 15735446 [PubMed - indexed for MEDLINE]Related articles

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13.PMID: 15167289 [PubMed - indexed for MEDLINE]Related articles

Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults.

Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84.PMID: 16878045 [PubMed - indexed for MEDLINE]Related articles

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.

Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.

HIV Med. 2006 Mar;7(2):99-104.PMID: 16420254 [PubMed - indexed for MEDLINE]Related articles